Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)
We present a personalized blood test for acute myeloid leukemia that tracks patient-specific circulating tumor DNA, enabling sensitive, universal, noninvasive detection of residual disease. It outperforms standard-of-care marrow and cell-based methods for predicting relapse and survival, including after transplant, reveals clonal dynamics, and supports individualized disease monitoring and risk-adapted treatment.
Authors
- Crystal Zhou (ORCID: https://orcid.org/0000-0002-0763-0721)
- Matthew Schwede (ORCID: https://orcid.org/0000-0002-0778-9230)
- Charu Tiwari
- Ruwan Gunaratne (ORCID: https://orcid.org/0009-0003-9798-4922)
- Matthew S. Alkaitis (ORCID: https://orcid.org/0000-0002-4193-8180)
- Michael S. Khodadoust (ORCID: https://orcid.org/0000-0001-9061-7351)
- Jesse W. Tai (ORCID: https://orcid.org/0000-0001-6556-4171)
- Sky Kim
- Brian J. Sworder (ORCID: https://orcid.org/0000-0002-5902-5507)
- David M. Kurtz (ORCID: https://orcid.org/0000-0002-6382-4651)
- Grace Gao (ORCID: https://orcid.org/0000-0002-1807-8637)
- Tian Yi Zhang (ORCID: https://orcid.org/0000-0002-6274-0763)
- Sanjeeth Rajaram (ORCID: https://orcid.org/0000-0002-9336-422X)
- Gabriel N. Mannis
- Emily Yang (ORCID: https://orcid.org/0000-0002-6028-2455)
- Raymond Yin (ORCID: https://orcid.org/0009-0009-4037-5994)
- Ravindra Majeti
- Kailee Tanaka
- Mia Carleton
Institutions
- City Of Hope National Medical Center (US)
- University of California, San Francisco (US)
- California Institute for Regenerative Medicine (US)
- Swedish Medical Center (US)
- Swedish Medical Center (US)
- City of Hope (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-02-04
- DOI
- https://doi.org/10.64898/2026.01.28.26344873
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00